[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638851":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":34,"centralContacts":38,"locations":44,"responsibleParty":63,"collaborators":28,"id":65,"slug":28,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":28,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":28,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":28,"overallStatus":47,"whyStopped":28,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"MK-7262","EXPERIMENTAL","Participants will receive MK-7262 orally.",[13],"Drug: MK-7262",{"label":15,"type":10,"description":16,"interventionNames":17},"Enlicitide","Participants will receive enlicitide orally.",[18],"Drug: Enlicitide",{"label":20,"type":10,"description":21,"interventionNames":22},"MK-7262 plus Enlicitide","Participants will receive MK-7262 and enlicitide orally.",[13,18],[24,29],{"type":25,"name":9,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Oral administration",[9,20],null,{"type":25,"name":15,"description":26,"armGroupLabels":30,"otherNames":31},[15,20],[32,33],"enlicitide decanoate","MK-0616",[35],{"name":36,"affiliation":5,"role":37},"Medical Director","STUDY_DIRECTOR",[39],{"name":40,"role":41,"phone":42,"phoneExt":28,"email":43},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"Celerion ( Site 0001)","RECRUITING","Lincoln","Nebraska","68502","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-96.66696,40.8,{"lat":57,"lon":56},[60],{"name":61,"role":41,"phone":62,"phoneExt":28,"email":28},"Study Coordinator","402-476-2811",{"type":64,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100638851",false,"NCT07619443","A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)","A Clinical Drug-Drug Interaction Study to Evaluate the Mutual Pharmacokinetic Effects of MK-7262 and Enlicitide in Healthy Participants","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Is in good health before randomization\n* Has a body mass index (BMI) ≥18 and ≤32 kg\u002Fm\\^2, inclusive\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history or presence of clinically significant medical or psychiatric condition or disease\n* Has a history of cancer",true,"ALL","19 Years","55 Years",{"count":76,"type":77},30,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","The goal of this study is to learn what happens to a single dose of enlicitide over time in a healthy participant's body when the participant is given a single dose of MK-7262 and what happens to a single dose of MK-7262 over time in a healthy participant's body when the participant is given a single dose of enlicitide.",[83],"Healthy","2026-06-26",{"date":86,"type":87},"2026-06-30","ACTUAL",{"date":89,"type":77},"2026-07-06",{"date":91,"type":77},"2026-09-12",{"name":5,"class":6},1]